What BioNTech’s £362 million AI acquisition says about the future of life sciences IP strategies
The convergence of tech and biopharma has major implications for patent professionals
The convergence of tech and biopharma has major implications for patent professionals
A string of deals announced during December and the beginning of January send a very clear message to policymakers and regulators
Sales of drug earnings streams is an increasingly popular means of monetising life sciences innovations
Purchase by Sino Biopharm subsidiary has been put on hold by US authorities
04 January 2023
Chinese company also extends 2017 patent licence agreement with Nokia
23 December 2022
New contender is a large firm that does not need external financing but original buyer Catapult IP Innovations is now in final negotiations with new financial partners
21 December 2022
The agreement is one of the largest single-asset deals of all time
19 December 2022
The year’s largest acquisition sees several IP-backed rare disease treatments change hands
15 December 2022
Data platform changes at the USPTO may mean transactions are being recorded more slowly than usual, says AST
08 December 2022
Imago BioSciences buyout is intended to diversify the company’s revenue streams
28 November 2022
Selling revenue streams is an increasingly important way of monetising pharma innovations
16 November 2022
An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done
11 November 2022
Strategic review of the licensing business nears a year in motion with no news on potential divestment announced
10 November 2022
Unlock unlimited access to all IAM content